Addendum
Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42
Report documents
-
Addendum
Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42
Dossier assessment
Indication:
Pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg
Result of dossier assessment:
Unchanged after addendum:
added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-11-02 A G-BA decision was published.
Project details
- Project no.
- A23-96
- Commission
- Commission awarded on 26.09.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
- https://doi.org/10.60584/A23-96
Connected Projects
-
Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed